compani
line ep street
pipelin street
conclus expect see preview rais
sales/ep rang third consecut quarter
vs midpoint project lli revis sale midpoint
our/street impli yoy growth ep midpoint
our/street sale
below/abov our/street est ep
beat our/street est encourag anoth beat-
and-rais major ep beat driven lower opex/tax
sale below/in-lin our/street estim driven miss
non-cor asset ciali adcirca anim health total sale
quarter yoy volum price fx
estim notabl beat cardiovascular anim health
miss diabet oncolog immunolog diabet posit top-
line data rewind empris support continu class leadership
trulic jardianc respect see note lli
co-agonist tirzepatid excit next-gen asset see
note lli neuro/pain deal dicerna buy edward nash
oct see note oncolog deal privat
low-financi risk early-stag collabor fit lli low-
risk busi develop bd style remain track launch new
product year-end begin emgal galcanezumab approv
sept migrain prophylaxi lasmiditan file acut migrain
pdufa tanezumab oa pain look forward updat
lli pipelin call includ earli feedback emgal launch well
discuss capit alloc bd prioriti go forward reiter
ep risk includ price pressur esp
rais sales/ep rang midpoint
rais narrow non-gaap ep rang
revis midpoint our/street
lli revenu target rais
revis midpoint vs our/street think
earli inning margin expans stori maintain gross
compani
margin target vs our/street also maintain rang
midpoint vs our/street rais narrow sg outlook
revis midpoint vs our/street
lower tax rate vs our/street exhibit breakdown
lli rang vs our/street estim
sale vs street diabetes/onc miss cv beat
total revenu yoy volum price fx below/
our/street est driven sale miss diabet oncolog partial off-set beat
cardiovascular anim health geograph us sale came vs
our/street ex-u revenu vs our/street estim
diabet beat vs our/street estim trulic humulin
off-set miss basaglar jardianc tradjenta
beat our/street estim alimta cyramza miss
immunolog report taltz sale vs our/street estim olumi
sale cardiovascular sale beat our/street estim
made weak growth asset diabet immunolog etc anim health sale
beat our/street well exhibit breakdown product
sale in-lin street ep beat
total sale yoy estimate mostli in-lin
street ep yoy
estim street rel estim lower cog lower
opex lower tax partial off-set lower sale gross margin vs
our/street our/street sg
below/abov our/street lli tax rate vs our/street
yield ep yoy our/street
exhibit breakdown pnl result vs our/street estim
catalyst-rich new product cycl unfold
preserv like stop earli interim analys opinion plan initi
program late aim file taltz treat ankylos spondyl
regul olumi initi psa/sl adapt initi alopecia
areata track file lasmiditan nda expect fda action dec
investor event focus financi ranges/pipelin progress product gain
hold lli full result tanezumab phase osteoarthr oa trial acr share
addit safeti detail case osteonecrosi rapidli progress osteoarthr ropa seen
tanezumab treat patient vs placebo arm pfe/lli expect three remain
trial tanezumab oa oa efficaci long-term safeti
chronic low back pain tango read earli announc posit top-lin data
trulic rewind expect full data ada june
page
compani
one-off guidanc updat sigilon deal
page
compani
interest net
page
compani
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
